FDA Approved Indications for this Orphan Drug:

Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib

FDA Marketing Approval issued as of:
12/11/2015

Orphan Drug exclusivity ends on:
12/11/2022
Company Making and Marketing this drug:
Genentech, Inc.

FDA Designation Date:
1/27/15

FDA Drug Designation:
Treatment of ALK-positive non-small cell lung cancer